Clinical Trial Detail

NCT ID NCT03206203
Title Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Carboplatin

Carboplatin

Age Groups: senior adult

No variant requirements are available.